Estimation of Advanced Glycation end-Products in Patients of Vitiligo

Document Type : Original Article

Authors

1 Dermatology department, dermatology and leprosy clinic,Beni-Suef , Ministry of Health, Egypt

2 Dermatology department, Faculty of Medicine, Beni-Suef University, Egypt

Abstract

The goal of this study is to detect a relationship between advanced glycation end-products and the pathogenesis of vitiligo in diseased patients as compared to normal control persons using Enzyme-Linked Immunosorbent Assay (ELISA) technique on tissue skin biopsy. The present study included 30 Egyptian vitiligo patients, their age ranged from (20 to 50 years). They were recruited from Dermatology outpatient clinic at Beni-Suef University hospital. Thirty unrelated apparent healthy controls with similar demographic (matched age and sex) were taken.The studied subjects were divided into two groups as follows, Group I: (n = 30) vitiligo patients and Group II: (n = 30) unrelated apparent healthy controls. Four mm punch skin biopsy will be taken from patients( vitiligo lesion) & control and it will be kept in lysis solution for the stability of the studied parameters and will be kept frozen at -80 Celsius till analysis of  advanced glycation end-products by ELISA. The result of the study showed that expression of AGEs in lesional skin of Vitiligo patients was significantly higher as compared to normal control persons.  Also reveled moderate negative correlation between the expression of Advanced Glycation end-Products (AGEs) in lesional skin of vitiligo patients and Vitiligo disease activity (VIDA) score of the studied cases and that confirms that AGE levels were, instead, significantly higher in vitiligo patients with older lesions.

Keywords

Main Subjects

References

  1. Taieb, A. and Picardo, M. (2009) : Clinical practice, Vitiligo. N Engl J Med 360: 160–169.
  2. Forschener, T.; Buchholtz, S. and Stockfleth, E. (2007): Current state of vitiligo therapy-evidence- based analysis of the literature. J. Dtsch. Dermatol.Ges.; 5: 467-75.
  3. Bossio C, Abdel Aziz I, Tullii G, Zucchetti E, Debellis D, Zangoli M, Di Maria F, Lanzani G, Antognazza.MR.( 2018): Vitiligo, reactive oxygen species and T-cells.Front Bioeng Biotechnol.;6:114.
  4. Jain A, Mal J, Mehndiratta V, Chander R, Patra SK (2011): Study of oxidative stress in vitiligo. Indian J Clin Biochem .; 26:78–81.
  5. Vaccaro, M., Bagnato, G., Cristani, M. et al.(2017): Oxidation products are increased in patients affected by non-segmental generalized vitiligo . Arch Dermatol Res .;309:485-490.
  6. Singh R1,Barden A,Mori T,Beilin L(2001): Advanced glycation end-products: a review.;44(2):129-46.
  7. Uribarri, Jaime; et al. (2010): Advanced Glycation End Products in Foods and a Practical Guide to Their Reduction in the Diet". Journal of the American Dietetic Association .;110 (6): 911–916.
  8. Vlassara H(1996): AGAs and atherosclerosis.Ann med .; 28:419-426.
  9. Vistoli, G; De Maddis, D; Cipak, A; Zarkovic, N; Carini, M; Aldini, G (2013): "Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation". Free Radic Res.; 47: Suppl 1:3–27.
  10. Yan,S.F.;D'Agati,V.;Schmidt,A.M.;Ramasamy,R.(2007):Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Current Molecular Medicine.; 7 (8): 699–710.
  11.  Alikhan, A., Felsten, L.M., Daly, M. and Petronic-Rosic, V. (2011):Vitiligo a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol.;65:473–491.
  12.  Allam, M., &Riad, H. (2014). Concise review of recent studies n vitiligo. Qatar medical journal,10.
  13.  Denat, L., Kadekaro, A. L., Marrot, L., Leachman, S. A., & Abdel-Malek, Z. A. (2014): Melanocytes as instigators and victims of oxidative stress. Journal of Investigative Dermatology, 134(6), 1512-1518.
  14.  Tessier FJ.(2010):The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol Biol (Paris).;58:9-214.
  15.  Bickers DR, Athar M (2006): Oxidative stress in the pathogenesis of skin disease. J Investig Dermatol .; 126:2565–2575.
  16.  Vaccaro M, Cicero F, Mannucci C, Calapai G, Spatari G, Barbuzza O, Cannavò SP, Gangemi S (2016): IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo. Arch Dermatol Res.; 308:527–530.
  17.  Jian Z, Li K, Song P, Zhu G, Zhu L, Cui T, Liu B, Tang L, Wang X, Wang G, Gao T, Li C .(2014): Impaired activation of the Nrf2- ARE signaling pathway undermines H2O2-induced oxidative stress response: a possible mechanism for melanocyte degenerationin vitiligo. J. Investig Dermatol .;134:2221-2222.
  18.  Saleem K, and Azim W (2016): Association of Vitiligo with Other Autoimmune Disorders. Diabetes Case Rep 1:114. doi: 10.4172/2572-5629.1000114.
  19.  Babar, Z. U. M., Alam, M., Khondker, L., Siddiqua, A., Alam, M. N., & Imdad, T. I. (2013): Association of other Autoimmune Diseases in Vitiligo Patients. Community Based Medical Journal, 2(2), 57-61.
  20.  Mario Vaccaro, Gianluca Bagnato2, Mariateresa Cristani3,Francesco Borgia1,Giovanna Spatari4, Valeria Tigano2, Antonina Saja3, Fabrizio Guarneri1 Serafinella P. Cannavo, Sebastiano Gangemi.(2017): Oxidation products are increased in patients affected by non-segmental generalized vitiligo.Arch Dermatol Res.;309:485–490.
  21.  Gu¨ntas¸ G, Engin B, Ekmekc¸i O ¨ B, Kutlubay Z, Ekmekci H, Songu¨r A, Uzunc¸akmak TK, Vehid HE, Serdarog˘lu S, Tu¨zu¨n Y, Uzun H .(2015): Evaluation of advanced oxidation protein products, prooxidant-antioxidant balance, and total antioxidant capacity in untreated vitiligo patients. Ann Dermatol.;27:178-183.

 

Files

Share

How to cite

Statistics